Overview

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Innovative Medical
Treatments:
Bimatoprost
Timolol
Travoprost